|
Accrued expenses consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
September 30,
2023 |
|
|
December 31,
2022 |
|
|
|
|
|
|
|
|
Accrued pre-clinical and clinical costs |
|
$ |
1,055,116 |
|
|
$ |
2,137,317 |
|
Accrued product development costs |
|
|
509,698 |
|
|
|
247,500 |
|
Accrued license costs |
|
|
2,825,000 |
|
|
|
— |
|
Accrued compensation |
|
|
1,669,980 |
|
|
|
2,224,951 |
|
Accrued administrative costs |
|
|
261,921 |
|
|
|
473,376 |
|
Accrued interest |
|
|
1,224,066 |
|
|
|
916,108 |
|
Total |
|
$ |
7,545,781 |
|
|
$ |
5,999,252 |
|
|